94 patents
Utility
Engineered Transferrin Receptor Binding Polypeptides
18 Jan 24
Provided herein are polypeptides that bind to a transferrin receptor, methods of generating such polypeptides, and methods of using the polypeptides to target a composition to a transferrin receptor-expressing cell.
Xiaocheng Chen, Mark S. Dennis, Mihalis Kariolis, Adam P. Silverman, Ankita Srivastava, Ryan J. Watts, Robert C. Wells, Joy Yu Zuchero
Filed: 11 Sep 23
Utility
Fusion proteins comprising enzyme replacement therapy enzymes
9 Jan 24
Provided herein are fusion proteins that comprise an enzyme replacement therapy enzyme and an Fc region, as well as methods of using such proteins to treat a lysosomal storage disorder.
Anastasia Henry, Mihalis S. Kariolis, Cathal S. Mahon, Adam P. Silverman, Ankita Srivastava, Julie Ullman
Filed: 23 Nov 20
Utility
Compounds, Compositions, and Methods
28 Dec 23
The present disclosure relates generally to small molecule modulators of NLR Family Pyrin Domain Containing 3 (NL-RP3), or a pharmaceutically acceptable salt, isotopically enriched analog, stereoisomer, mixture of stereoisomers, or prodrug thereof, methods of making and intermediates thereof, and methods of using thereof.
Alex L. Bagdasarian, Cyril Bucher, Robert A. Craig, II, Javier de Vicente Fidalgo, Anthony A. Estrada, Brian M. Fox, Cheng Hu, Benjamin J. Huffman, Katrina W. Lexa, Lizanne G. Nilewski, Maksim Osipov, Arun Thottumkara
Filed: 19 Nov 21
Utility
Fusion Proteins Comprising Progranulin
21 Dec 23
Provided herein are fusion proteins that comprise progranulin and an Fc polypeptide.
Gilbert Di Paolo, Todd P. Logan, Kathryn M. Monroe, Ankita Srivastava, Bettina Van Lengerich
Filed: 12 Apr 23
Utility
Substituted pyrimidines as LRKK2 inhibitors
12 Dec 23
Anthony A. Estrada, Jianwen A. Feng, Joseph P. Lyssikatos, Zachary K. Sweeney, Javier de Vicente Fidalgo
Filed: 7 Jun 21
Utility
Process for the preparation of pyrimidinyl-4-aminopyrazole compounds
5 Dec 23
Travis Remarchuk, Anantha Sudhakar
Filed: 19 Dec 18
Utility
Compounds, compositions, and methods
5 Dec 23
The present disclosure relates generally to LRRK2 inhibitors, or a pharmaceutically acceptable salt, deuterated analog, prodrug, tautomer, stereoisomer, or mixture of stereoisomers thereof, and methods of making and using thereof.
Javier de Vicente Fidalgo, Anthony A. Estrada, Jianwen A. Feng, Joseph P. Lyssikatos, Zachary K. Sweeney
Filed: 19 Jan 23
Utility
Affinity-based Methods for Using Transferrin Receptor-binding Proteins
30 Nov 23
Provided herein are methods for transporting agents across the blood brain barrier.
Mark S. Dennis, Jennifer Getz, Mihalis Kariolis, Adam P. Silverman, Robert C. Wells, Joy Yu Zuchero
Filed: 8 Feb 23
Utility
Compounds, Compositions and Methods
9 Nov 23
The present disclosure relates generally to small molecule modulators of NLR Family Pyrin Domain Containing 3 (NL-RP3), or a pharmaceutically acceptable salt, isotopically enriched analog, stereoisomer, mixture of stereoisomers, or prodrug thereof, methods of making and intermediates thereof, and methods of using thereof.
Alex L. Bagdasarian, Robert A. Craig, II, Javier de Vicente Fidalgo, Anthony A. Estrada, Brian M. Fox, Cheng Hu, Benjamin J. Huffman, Katrina W. Lexa, Lizanne G. Nilewski, Maksim Osipov, Arun Thottumkara
Filed: 13 Aug 21
Utility
Compounds, Compositions and Methods
2 Nov 23
The present disclosure relates generally to small molecule modulators of NLR Family Pyrin Domain Containing 3 (NL-RP3), or a pharmaceutically acceptable salt, isotopically enriched analog, stereoisomer, mixture of stereoisomers, or prodrug thereof, methods of making and intermediates thereof, and methods of using thereof.
Robert A. Craig, II, Javier de Vicente Fidalgo, Anthony A. Estrada, Brian M. Fox, Cheng Hu, Katrina W. Lexa, Lizanne G. Nilewski, Maksim Osipov, Arun Thottumkara
Filed: 1 Jul 21
Utility
Engineered transferrin receptor binding polypeptides
24 Oct 23
Provided herein are polypeptides that bind to a transferrin receptor, methods of generating such polypeptides, and methods of using the polypeptides to target a composition to a transferrin receptor-expressing cell.
Xiaocheng Chen, Mark S. Dennis, Mihalis Kariolis, Adam P. Silverman, Ankita Srivastava, Ryan J. Watts, Robert C. Wells, Joy Yu Zuchero
Filed: 16 Aug 19
Utility
Anti-BACE1 antibodies and methods of use thereof
3 Oct 23
In one aspect, antibodies that specifically bind to a human BACE1 protein are provided herein.
Mark S. Dennis, Jennifer A. Getz, Rinkan Shukla, Adam P. Silverman, Yin Zhang, Joy Yu Zuchero
Filed: 6 May 20
Utility
Crystalline Forms of (S)-5-BENZYL-N-(5-METHYL-4-OXO-2,3,4,5-TETRAHYDROPYRIDO [3,2-B][1,4]OXAZEPIN-3-YL)-4H-1,2,4-TRIAZOLE-3-CARBOXAMIDE
31 Aug 23
Described herein are crystalline forms of (S)-5-benzyl-N-(5-methyl-4-oxo-2,3,4,5-tetrahydropyrido [3,2-b][1,4]oxazepin-3-yl)-4H-1,2,4-triazole-3-carboxamide, the process of preparing the forms, and pharmaceutical compositions methods of use thereof.
Anantha Sudhakar
Filed: 11 Jan 23
Utility
Engineered polypeptides
22 Aug 23
Provided herein are polypeptides that bind to a blood-brain barrier (BBB) receptor, methods of generating such polypeptides, and methods of using the polypeptides to target a composition to a BBB receptor-expressing cell, e.g., for transport across the BBB.
Xiaocheng Chen, Mihalis Kariolis, Robert C. Wells
Filed: 17 Sep 19
Utility
Modulators of Eukaryotic Initiation Factor 2
10 Aug 23
Robert A. Craig, II, Javier de Vicente Fidalgo, Anthony A. Estrada, Jianwen A. Feng, Brian M. Fox, Katrina W. Lexa, Maksim Osipov, Zachary K. Sweeney, Arun Thottumkara
Filed: 14 Apr 23
Utility
Methods of Engineering Transferrin Receptor Binding Polypeptides
27 Jul 23
Provided herein are polypeptides that bind to a transferrin receptor, methods of generating such polypeptides, and methods of using the polypeptides to target a composition to a transferrin receptor-expressing cell.
Xiaocheng Chen, Mark S. Dennis, Mihalis Kariolis, Adam P. Silverman, Ankita Srivastava, Ryan J. Watts, Robert C. Wells, Joy Yu Zuchero
Filed: 15 Aug 22
Utility
Compounds, Compositions, and Methods
20 Jul 23
The present disclosure relates generally to LRRK2 inhibitors, or a pharmaceutically acceptable salt, deuterated analog, prodrug, tautomer, stereoisomer, or mixture of stereoisomers thereof, and methods of making and using thereof.
Javier de Vicente Fidalgo, Anthony A. Estrada, Jianwen A. Feng, Joseph P. Lyssikatos, Zachary K. Sweeney
Filed: 19 Jan 23
Utility
Phospho-Rab antibodies, assays and methods of use thereof
30 May 23
In one aspect, antibodies that specifically bind to a phosphorylated Rab protein are provided.
Jason C. Dugas, Anastasia Henry, Sarah Huntwork-Rodriguez, Michael T. Maloney, Nathan Moerke, Ella Negrou, Xiang Wang
Filed: 15 Jun 18
Utility
Progranulin variants
9 May 23
Provided herein are progranulin variants and fusion proteins that comprise a progranulin variant and an Fc polypeptide.
Gerald Maxwell Cherf, Gunasekaran Kannan, Katrina W. Lexa, Ray L. Y. Low, Rachel Prorok, Ankita Srivastava
Filed: 17 Mar 22
Utility
CorrectedMethods for Treating Dysregulated Lipid Metabolism
27 Apr 23
Certain embodiments described herein provide a method for treating dysregulated lipid metabolism and/or inflammation in a mammal in need thereof, comprising administering to the mammal an effective amount of an agonist anti-triggering receptor expressed on myeloid cells 2 (TREM2) antibody.
Giuseppe ASTARITA, Gilbert DI PAOLO, Kai Lin LIN, Kathryn M. MONROE, Alicia A. NUGENT, Bettina VAN LENGERICH
Filed: 26 Nov 19